|
Gene: DLC1 |
Gene summary for DLC1 |
Gene summary. |
Gene information | Species | Human | Gene symbol | DLC1 | Gene ID | 10395 |
Gene name | DLC1 Rho GTPase activating protein | |
Gene Alias | ARHGAP7 | |
Cytomap | 8p22 | |
Gene Type | protein-coding | GO ID | GO:0000902 | UniProtAcc | A8K119 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
10395 | DLC1 | P5T-E | Human | Esophagus | ESCC | 1.53e-03 | 1.66e-01 | 0.1327 |
10395 | DLC1 | P8T-E | Human | Esophagus | ESCC | 4.92e-02 | 7.89e-02 | 0.0889 |
10395 | DLC1 | P9T-E | Human | Esophagus | ESCC | 1.30e-05 | 2.74e-01 | 0.1131 |
10395 | DLC1 | P10T-E | Human | Esophagus | ESCC | 1.15e-10 | 2.17e-01 | 0.116 |
10395 | DLC1 | P11T-E | Human | Esophagus | ESCC | 2.98e-15 | 6.93e-01 | 0.1426 |
10395 | DLC1 | P16T-E | Human | Esophagus | ESCC | 2.26e-03 | 6.17e-02 | 0.1153 |
10395 | DLC1 | P19T-E | Human | Esophagus | ESCC | 2.29e-07 | 8.23e-01 | 0.1662 |
10395 | DLC1 | P22T-E | Human | Esophagus | ESCC | 7.33e-04 | 6.40e-02 | 0.1236 |
10395 | DLC1 | P24T-E | Human | Esophagus | ESCC | 7.37e-05 | 2.48e-01 | 0.1287 |
10395 | DLC1 | P28T-E | Human | Esophagus | ESCC | 1.44e-02 | 5.81e-02 | 0.1149 |
10395 | DLC1 | P42T-E | Human | Esophagus | ESCC | 3.16e-03 | 2.56e-01 | 0.1175 |
10395 | DLC1 | P44T-E | Human | Esophagus | ESCC | 2.68e-05 | 2.06e-01 | 0.1096 |
10395 | DLC1 | P47T-E | Human | Esophagus | ESCC | 2.47e-05 | 1.08e-01 | 0.1067 |
10395 | DLC1 | P52T-E | Human | Esophagus | ESCC | 3.67e-02 | 1.43e-01 | 0.1555 |
10395 | DLC1 | P57T-E | Human | Esophagus | ESCC | 4.18e-02 | 1.26e-01 | 0.0926 |
10395 | DLC1 | P75T-E | Human | Esophagus | ESCC | 2.08e-08 | 1.28e-01 | 0.1125 |
10395 | DLC1 | P76T-E | Human | Esophagus | ESCC | 7.10e-06 | 7.86e-02 | 0.1207 |
10395 | DLC1 | P79T-E | Human | Esophagus | ESCC | 1.85e-02 | 6.70e-02 | 0.1154 |
10395 | DLC1 | P89T-E | Human | Esophagus | ESCC | 6.03e-05 | 7.21e-01 | 0.1752 |
10395 | DLC1 | P130T-E | Human | Esophagus | ESCC | 5.53e-03 | 4.14e-02 | 0.1676 |
Page: 1 2 3 4 5 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0045862111 | Esophagus | ESCC | positive regulation of proteolysis | 256/8552 | 372/18723 | 7.88e-20 | 9.43e-18 | 256 |
GO:2000116111 | Esophagus | ESCC | regulation of cysteine-type endopeptidase activity | 158/8552 | 235/18723 | 1.67e-11 | 5.90e-10 | 158 |
GO:0043281111 | Esophagus | ESCC | regulation of cysteine-type endopeptidase activity involved in apoptotic process | 143/8552 | 209/18723 | 2.12e-11 | 7.31e-10 | 143 |
GO:1902903111 | Esophagus | ESCC | regulation of supramolecular fiber organization | 237/8552 | 383/18723 | 9.06e-11 | 2.75e-09 | 237 |
GO:0150115110 | Esophagus | ESCC | cell-substrate junction organization | 77/8552 | 101/18723 | 3.46e-10 | 9.57e-09 | 77 |
GO:0010952111 | Esophagus | ESCC | positive regulation of peptidase activity | 133/8552 | 197/18723 | 4.31e-10 | 1.14e-08 | 133 |
GO:000704418 | Esophagus | ESCC | cell-substrate junction assembly | 73/8552 | 95/18723 | 5.27e-10 | 1.35e-08 | 73 |
GO:0052547111 | Esophagus | ESCC | regulation of peptidase activity | 275/8552 | 461/18723 | 7.54e-10 | 1.88e-08 | 275 |
GO:0010639110 | Esophagus | ESCC | negative regulation of organelle organization | 215/8552 | 348/18723 | 8.20e-10 | 2.01e-08 | 215 |
GO:001631110 | Esophagus | ESCC | dephosphorylation | 251/8552 | 417/18723 | 1.26e-09 | 2.99e-08 | 251 |
GO:003158919 | Esophagus | ESCC | cell-substrate adhesion | 221/8552 | 363/18723 | 3.06e-09 | 6.62e-08 | 221 |
GO:000647018 | Esophagus | ESCC | protein dephosphorylation | 177/8552 | 281/18723 | 3.13e-09 | 6.72e-08 | 177 |
GO:001081020 | Esophagus | ESCC | regulation of cell-substrate adhesion | 144/8552 | 221/18723 | 3.55e-09 | 7.45e-08 | 144 |
GO:000184115 | Esophagus | ESCC | neural tube formation | 75/8552 | 102/18723 | 9.68e-09 | 1.95e-07 | 75 |
GO:000184314 | Esophagus | ESCC | neural tube closure | 66/8552 | 88/18723 | 1.98e-08 | 3.82e-07 | 66 |
GO:000701527 | Esophagus | ESCC | actin filament organization | 259/8552 | 442/18723 | 2.37e-08 | 4.50e-07 | 259 |
GO:004804116 | Esophagus | ESCC | focal adhesion assembly | 65/8552 | 87/18723 | 3.28e-08 | 6.08e-07 | 65 |
GO:0052548111 | Esophagus | ESCC | regulation of endopeptidase activity | 253/8552 | 432/18723 | 3.68e-08 | 6.78e-07 | 253 |
GO:001402014 | Esophagus | ESCC | primary neural tube formation | 69/8552 | 94/18723 | 4.22e-08 | 7.76e-07 | 69 |
GO:006060614 | Esophagus | ESCC | tube closure | 66/8552 | 89/18723 | 4.24e-08 | 7.76e-07 | 66 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
DLC1 | SNV | Missense_Mutation | rs144283917 | c.1051N>T | p.Arg351Trp | p.R351W | Q96QB1 | protein_coding | deleterious_low_confidence(0.02) | probably_damaging(0.998) | TCGA-EP-A3RK-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD |
DLC1 | SNV | Missense_Mutation | c.2273C>T | p.Pro758Leu | p.P758L | Q96QB1 | protein_coding | tolerated(0.12) | probably_damaging(0.997) | TCGA-G3-A7M6-01 | Liver | liver hepatocellular carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
DLC1 | SNV | Missense_Mutation | c.2596N>T | p.Arg866Cys | p.R866C | Q96QB1 | protein_coding | tolerated(0.1) | benign(0.075) | TCGA-05-4395-01 | Lung | lung adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |
DLC1 | SNV | Missense_Mutation | c.4468N>C | p.Gly1490Arg | p.G1490R | Q96QB1 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-05-5425-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Targeted Molecular therapy | gefitinib | PD | |
DLC1 | SNV | Missense_Mutation | c.56N>T | p.Gly19Val | p.G19V | Q96QB1 | protein_coding | deleterious_low_confidence(0) | benign(0.231) | TCGA-44-6778-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
DLC1 | SNV | Missense_Mutation | novel | c.3442N>A | p.Asp1148Asn | p.D1148N | Q96QB1 | protein_coding | deleterious(0.02) | probably_damaging(0.976) | TCGA-44-7662-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
DLC1 | SNV | Missense_Mutation | c.2981N>T | p.Arg994Met | p.R994M | Q96QB1 | protein_coding | deleterious(0) | possibly_damaging(0.854) | TCGA-44-7670-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD | |
DLC1 | SNV | Missense_Mutation | c.827N>C | p.Ser276Thr | p.S276T | Q96QB1 | protein_coding | deleterious_low_confidence(0.01) | benign(0) | TCGA-49-AARE-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
DLC1 | SNV | Missense_Mutation | c.1585G>T | p.Asp529Tyr | p.D529Y | Q96QB1 | protein_coding | deleterious(0) | probably_damaging(0.976) | TCGA-49-AARQ-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
DLC1 | SNV | Missense_Mutation | rs150963046 | c.463N>A | p.Gln155Lys | p.Q155K | Q96QB1 | protein_coding | tolerated_low_confidence(0.2) | benign(0) | TCGA-50-6592-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |